← Leaderboards
Nathan P Staff
Mayo Clinic Rochester
$5,882,116
Attributed
$6,071,882
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,071,882 · 6
By mechanism
R01$3,559,536 · 2
U24$1,348,851 · 1
K08$721,980 · 1
R21$379,533 · 1
F30$61,982 · 1
Top collaborators
- Jennifer J. Westendorf2 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Eduardo N Chini$9,940,387
- Sandra M Herrmann$800,160
- Arun Kanakkanthara$1,775,030
- David O Warner$17,454,427
- Sarah Eby$157,921
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventPainPeripheral Nervous System DiseasesMalignant NeoplasmsChemotherapyIn VitroChemotherapy-Induced Peripheral NeuropathyNeuronsAfferent NeuronsExperimental StudyMitochondriaInduced Pluripotent Stem CellBasePathway InteractionsRodentDistalSpinal GangliaInnovationCell LineNeuroprotectionHuman BiologyClustered Regularly Interspaced Short Palindromic RepeatsNeurotoxicDose
Grant awards (20)
Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity$622,064
R01 · FY2025 · CA · contact PI
The Mayo Clinic NeuroNEXT Clinical Research Site$443,875
U24 · FY2025 · NS · contact PI
Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity$550,425
R01 · FY2024 · CA · contact PI
The Mayo Clinic NeuroNEXT Clinical Research Site$435,680
U24 · FY2024 · NS · contact PI
PHLPP inhibition and Osteoarthritis-Associated Pain$169,653
R21 · FY2024 · AR
Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity$579,394
R01 · FY2023 · CA · contact PI
The Mayo Clinic NeuroNEXT Clinical Research Site$469,296
U24 · FY2023 · NS · contact PI
PHLPP inhibition and Osteoarthritis-Associated Pain$209,880
R21 · FY2023 · AR
Assessment of Chemotherapy-Induced Peripheral Neuropathy Susceptibility Using Patient-derived iPSC Technology$363,713
R01 · FY2021 · CA · contact PI
Assessment of Chemotherapy-Induced Peripheral Neuropathy Susceptibility Using Patient-derived iPSC Technology$363,713
R01 · FY2020 · CA · contact PI
Assessment of Chemotherapy-Induced Peripheral Neuropathy Susceptibility Using Patient-derived iPSC Technology$352,801
R01 · FY2019 · CA · contact PI
Assessment of Chemotherapy-Induced Peripheral Neuropathy Susceptibility Using Patient-derived iPSC Technology$363,713
R01 · FY2018 · CA · contact PI
Assessment of Chemotherapy-Induced Peripheral Neuropathy Susceptibility Using Patient-derived iPSC Technology$363,713
R01 · FY2017 · CA · contact PI
Mechanisms of Bortezomib-induced Peripheral Neuropathy$144,396
K08 · FY2016 · CA · contact PI
Mechanisms of Bortezomib-induced Peripheral Neuropathy$144,396
K08 · FY2015 · CA · contact PI
Mechanisms of Bortezomib-induced Peripheral Neuropathy$144,396
K08 · FY2014 · CA · contact PI
Mechanisms of Bortezomib-induced Peripheral Neuropathy$144,396
K08 · FY2013 · CA · contact PI
Mechanisms of Bortezomib-induced Peripheral Neuropathy$144,396
K08 · FY2012 · CA · contact PI
Dopaminergic modulation of CA1 intrinsic excitability$9,022
F30 · FY2004 · DA
Dopaminergic modulation of CA1 intrinsic excitability$52,960
F30 · FY2003 · DA